TuHURA Biosciences Q3 R&D Expenses Fall 26% to $3.7 Million

• TuHURA Biosciences’ third-quarter 2026 research and development expenses fell 26% year-over-year to $3.7 million due to lower manufacturing costs.
• General and administrative expenses rose 25% year-over-year to $2 million, primarily due to higher noncash stock compensation and public-company costs.
• Operating cash outflows narrowed 18% year-over-year to $18.1 million for the nine months ended September 30, 2026.
• Cash and cash equivalents totaled $1.9 million at September 30; the Parkview loan facility provided $5.6 million during the third quarter.
• FDA clearance allows a Phase 1b trial of TBS-2025 in relapsed or refractory mutNPM1 acute myeloid leukemia following menin inhibitor treatment failure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611130745PR_NEWS_USPR_____LA96931) on November 13, 2026, and is solely responsible for the information contained therein.